| Levitan B et al. (2014). Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. |
A) Major bleeding
Rivaroxaban – 75 in 10,000
Enoxaparin – 48 in 10,000
B) Minor bleeding + surgical site
Rivaroxaban – 189 in 10,000
Enoxaparin – 141 in 10,000 |
A) Symptomatic venous thromboembolism
Rivaroxaban – 102 cases in 10,000
Enoxaparin – 178 cases in 10,000
B) Mortality
Rivaroxaban – 23 cases in 10,000
Enoxaparin – 42 cases in 10,000 |
| Li J et al. (2014). Comparison of rivaroxaban and enoxaparin on blood loss after total knee arthroplasty. |
A) Visible blood loss
Enoxaparin greater than rivaroxaban (p=0.003)
B) Total blood loss
No difference between groups
C) Occult blood loss
Rivaroxaban greater than enoxaparin (p=0.000) |
Not rated. |
| Turpie AG et al. (2014). A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopedic surgery in 17,701 patients with propensity score adjustment. |
A) Major bleeding
Rivaroxaban – 35 in 8548 cases
Enoxaparin – 27 in 7968 cases
OR weighted (95% CI) – 1.35 (0.94-1.93)
B) Minor bleeding
Rivaroxaban – 365 in 8548 cases
Enoxaparin – 232 in 7968 cases
OR weighted (95% IC) - 1.52 (1.35-1.71) |
A) Symptomatic venous thromboembolism
Rivaroxaban (intervention) – 77 in 8548 cases
Enoxaparin (control) – 104 in 7968 cases
OR weighted (95%CI) – 0 69 (0.56-0.85)
B) Mortality
Rivaroxaban – 7 in 8548 cases
Enoxaparin – 7 in 7968 cases
OR weighted (95% IC) – 1.00 (0.53-2.00) |
| Sindali et al. (2013). Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. |
A) Minor occult bleeding
Rivaroxaban - 2%
Enoxaparin - 0%
B) Bleeding in the wound
Rivaroxaban – 5%
Enoxaparin – 1.8%
There was no statistical difference. |
A) Venous thromboembolism
Rivaroxaban – 2 in 202 (1%)
Enoxaparin – 1 in 59 (1.8%); p=0.52 |
| Lassen MR et al. (2012). The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. |
A) Postoperative bleeding
Rivaroxaban – 19 in 2746 (0.69)
Enoxaparin – 19 in 2747 (0.69) |
A) Serious adverse events
Rivaroxaban – 224 in 2,746 (8.16)
Enoxaparin – 272 in 2,747 (9.90) |
| Gómez-Outes A et al. (2012). Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, systematic review, meta-analysis, and indirect treatment comparisons. |
A) Major bleeding
Rivaroxaban – 123 in 2940
Enoxaparin – 96 in 2946
RR (95% CI) – 1.29 (0.99-1.67) |
A) Symptomatic venous thromboembolism
Rivaroxaban – 21 in 2940
Enoxaparin – 44 in 2946
RR (95% CI) – 0.49 (0.29 to 0.83) |
| Nieto JA et al. (2012). Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: Pool-analysis of phase III randomized clinical trials. |
A) Major bleeding
Rivaroxaban – 23 in 4955
Enoxaparin – 1 in 4971
B) Total bleeding (major and minor clinically relevant)
Rivaroxaban – 160 in 4955
Enoxaparin – 124 in 4971 |
A) Venous thromboembolism
Rivaroxaban – 34 in 4036
Enoxaparin – 99 in 4064
RR (95% CI) – 0.32 (0.15-0.67) |
| Eriksson BI et al. (2012). Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. |
A) Any bleeding
Rivaroxaban + ASA (95% CI) - 1.43 (1.03-1.98)
Enoxaparin + ASA (95% CI) - 1.41 (0.98-2.04) |
Not rated. |
| Zou et al. (2014). Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. |
A) Hidden lesser bleeding
Rivaroxaban – 1.71 (1.19 to 2.97)
Enoxaparin – 1.18 (0.77 to 2.31)
B) Complications in the wound
Rivaroxaban – 5 cases in 102 (4.90%)
Enoxaparin – 3 cases in 112 (2.67%) |
A) Distal venous thromboembolism
Rivaroxaban – 3 in 102 cases
Enoxaparin – 14 in 112 cases
B) Pulmonary thromboembolism
None of the analyzed groups. |
